Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab
Conditions
Interventions
Rituximab
N-803
Locations
4
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
Washington University School of Medicine Oncology
St Louis, Missouri, United States
The Ohio State University
Columbus, Ohio, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Start Date
April 17, 2015
Primary Completion Date
December 13, 2020
Completion Date
December 13, 2020
Last Updated
July 3, 2024
Lead Sponsor
Altor BioScience
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions